FGFR4 Arg388 genotype is associated with pathological complete response to neoadjuvant chemotherapy for primary breast cancer

Annals of Oncology

Volumn 21, Issue 8, 2010, Pages 1636-1642

  Marme F ^a,b   Werft, W ^b   Benner, A ^b   Burwinkel, B ^a,b   Sinn, P ^b   Sohn, C ^a   Lichter, P ^b   Hahn, M ^b   Schneeweiss, A ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Breast cancer; FGFR4; Neoadjuvant therapy; Pathological complete response; Predictive factor; Single nucleotide polymorphism

Indexed keywords

ARGININE; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; FIBROBLAST GROWTH FACTOR RECEPTOR 4; GENOMIC DNA; GLYCINE; PEMETREXED;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ALLELE; ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE COMPARISON; GENE INTERACTION; GENETIC ASSOCIATION; GENOTYPE; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; HUMAN TISSUE; JOINT FUNCTION; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; PHASE 2 CLINICAL TRIAL; PREDICTION; PRIMARY BREAST CANCER; PRIORITY JOURNAL; PROGNOSIS; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ARGININE; BASE SEQUENCE; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DNA PRIMERS; FEMALE; GENOTYPE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; PROGNOSIS; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 4; REMISSION INDUCTION;

EID: 77955240761     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq017     Document Type: Article

References (38)

1. Kaufmann M, von Minckwitz G, Bear HD et al. Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006. Ann Oncol 2007; 18: 1927-1934.
2. Rastogi P, Anderson SJ, Bear HD et al. Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J Clin Oncol 2008; 26: 778-785.
3. Liedtke C, Mazouni C, Hess KR et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol 2008; 26: 1275-1281.
4. Guarneri V, Broglio K, Kau SW et al. Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors. J Clin Oncol 2006; 24: 1037-1044.
5. EBCTCG. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 365: 1687-1717.
6. Powers CJ, McLeskey SW, Wellstein A. Fibroblast growth factors, their receptors and signaling. Endocr Relat Cancer 2000; 7: 165-197.
7. Burke D, Wilkes D, Blundell TL, Malcolm S. Fibroblast growth factor receptors: lessons from the genes. Trends Biochem Sci 1998; 23: 59-62
8. Bange J, Prechtl D, Cheburkin Y et al. Cancer progression and tumor cell motility are associated with the FGFR4 Arg(388) allele. Cancer Res 2002; 62: 840-847.
9. Stadler CR, Knyazev P, Bange J, Ullrich A. FGFR4 GLY388 isotype suppresses motility of MDA-MB-231 breast cancer cells by EDG-2 gene repression. Cell Signal 2006; 18: 783-794.
10. Thussbas C, Nahrig J, Streit S et al. FGFR4 Arg388 allele is associated with resistance to adjuvant therapy in primary breast cancer. J Clin Oncol 2006; 24: 3747-3755.
11. Ansell A, Farnebo L, Grenman R et al. Polymorphism of FGFR4 in cancer development and sensitivity to cisplatin and radiation in head and neck cancer. Oral Oncol 2009; 45: 23-29.
12. da Costa Andrade VC, Parise O Jr., Hors CP et al. The fibroblast growth factor receptor 4 (FGFR4) Arg388 allele correlates with survival in head and neck squamous cell carcinoma. Exp Mol Pathol 2007; 82: 53-57.
13. Morimoto Y, Ozaki T, Ouchida M et al. Single nucleotide polymorphism in fibroblast growth factor receptor 4 at codon 388 is associated with prognosis in high-grade soft tissue sarcoma. Cancer 2003; 98: 2245-2250.
14. Spinola M, Leoni V, Pignatiello C et al. Functional FGFR4 Gly388Arg polymorphism predicts prognosis in lung adenocarcinoma patients. J Clin Oncol 2005; 23: 7307-7311.
15. Streit S, Mestel DS, Schmidt M et al. FGFR4 Arg388 allele correlates with tumour thickness and FGFR4 protein expression with survival of melanoma patients. Br J Cancer 2006; 94: 1879-1886.
16. Wang J, Stockton DW, Ittmann M. The fibroblast growth factor receptor-4 Arg388 allele is associated with prostate cancer initiation and progression. Clin Cancer Res 2004; 10: 6169-6178.
17. Yang YC, Lu ML, Rao JY et al. Joint association of polymorphism of the FGFR4 gene and mutation TP53 gene with bladder cancer prognosis. Br J Cancer 2006; 95: 1455-1458.
18. Becker N, Nieters A, Chang-Claude J. The fibroblast growth factor receptor gene Arg388 allele is not associated with early lymph node metastasis of breast cancer. Cancer Epidemiol Biomarkers Prev 2003; 12: 582-583.
19. Jezequel P, Campion L, Joalland MP et al. G388R mutation of the FGFR4 gene is not relevant to breast cancer prognosis. Br J Cancer 2004; 90: 189-193.
20. Matakidou A, El Galta R, Rudd MF et al. Further observations on the relationship between the FGFR4 Gly388Arg polymorphism and lung cancer prognosis. Br J Cancer 2007; 96: 1904-1907.
21. Mawrin C, Kirches E, Diete S et al. Analysis of a single nucleotide polymorphism in codon 388 of the FGFR4 gene in malignant gliomas. Cancer Lett 2006; 239: 239-245.
22. Spinola M, Leoni VP, Tanuma J et al. FGFR4 Gly388Arg polymorphism and prognosis of breast and colorectal cancer. Oncol Rep 2005; 14: 415-419.
23. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-216.
24. van Buuren S, Groothuis-Oudshoorn CGM, Rubin DB. Fully conditional specifications in multivariate imputation. J Stat Comput Simul 2006; 76: 1049-1064.
25. Schneeweiss A, Ruiz A, Rovira P. Results of clinical endpoints of a randomized phase II trial with doxorubicin+pemetrexed followed by docetaxel versus doxorubicin+cyclophosphamide followed by docetaxel as primary systemic therapy for early breast cancer. Breast 2009; 18 (Suppl 1): S63 (Abstr 0178).
26. Beverage JN, Sissung TM, Sion AM et al. CYP2D6 polymorphisms and the impact on tamoxifen therapy. J Pharm Sci 2007; 96: 2224-2231.
27. Goetz MP, Kamal A, Ames MM. Tamoxifen pharmacogenomics: the role of CYP2D6 as a predictor of drug response. Clin Pharmacol Ther 2008; 83: 160-166.
28. Lim HS, Ju Lee H, Seok Lee K et al. Clinical implications of CYP2D6 genotypes predictive of tamoxifen pharmacokinetics in metastatic breast cancer. J Clin Oncol 2007; 25: 3837-3845.
29. Schroth W, Antoniadou L, Fritz P et al. Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes. J Clin Oncol 2007; 25: 5187-5193.
30. Xu Y, Yao L, Ouyang T et al. p53 Codon 72 polymorphism predicts the pathologic response to neoadjuvant chemotherapy in patients with breast cancer. Clin Cancer Res 2005; 11: 7328-7333.
31. Green H, Soderkvist P, Rosenberg P et al. mdr-1 single nucleotide polymorphisms in ovarian cancer tissue: G2677T/A correlates with response to paclitaxel chemotherapy. Clin Cancer Res 2006; 12: 854-859.
32. Green H, Soderkvist P, Rosenberg P et al. ABCB1 G1199A polymorphism and ovarian cancer response to paclitaxel. J Pharm Sci 2008; 97: 2045-2048.
33. Ho HK, Pok S, Streit S et al. Fibroblast growth factor receptor 4 regulates proliferation, anti-apoptosis and alpha-fetoprotein secretion during hepatocellular carcinoma progression and represents a potential target for therapeutic intervention. J Hepatol 2009; 50: 118-127.
34. Dent R, Trudeau M, Pritchard KI et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 2007; 13: 4429-4434.
35. von Minckwitz GKM, Kümmel S, Fasching P et al. Integrated meta-analysis on 6402 patients with early breast cancer receiving neoadjuvant anthracycline-taxane +/- trastuzumab containing chemotherapy In San Antonio Breast Cancer Symposium. San Antonio, TX 2008: (Abstr 79).
36. Ezzat S, Huang P, Dackiw A, Asa SL. Dual inhibition of RET and FGFR4 restrains medullary thyroid cancer cell growth. Clin Cancer Res 2005; 11: 1336-1341.
37. Gowardhan B, Douglas DA, Mathers ME et al. Evaluation of the fibroblast growth factor system as a potential target for therapy in human prostate cancer. Br J Cancer 2005; 92: 320-327.
38. St Bernard R, Zheng L, Liu W et al. Fibroblast growth factor receptors as molecular targets in thyroid carcinoma. Endocrinology 2005; 146: 1145-1153.